Patients n | Mortality rate % | ||||||
In-hospital | 3 months | 6 months | 1 yr | 2 yrs | 5 yrs | ||
Studies included in the meta-analysis | |||||||
Connors 15 | 1016 | 11 | NR | 33 | 43 | 49 | NR |
Vestbo 16 | 487 | NR | NR | NR | NR | NR | 44 |
Groenewegen 17 | 171 | 8 | 16 | 18 | 23 | NR | NR |
Gunen 18 | 205 | 8.3 | NR | 24 | 33 | 39 | NR |
McGhan 19 | 54269 | 3.6 | NR | NR | 24 | NR | 57 |
Brekke 20 | 996 | 9.9 | 22 | 27 | 32 | 41 | NR |
Studies excluded from the meta-analysis# | |||||||
Fuso 10 | 590 | 14 | NR | NR | NR | NR | NR |
Cydulka 21¶ | 131974 | 6 | NR | NR | NR | NR | NR |
Eriksen 22 | 300 | 8.6 | 19 | NR | 36 | NR | NR |
Patil 9 | 71130 | 2.5 | NR | NR | NR | NR | NR |
Yohannes 23 | 104 | 3.8 | NR | NR | 38 | NR | NR |
Wang 24 | 282 | 9.9 | NR | NR | NR | NR | NR |
Price 25 | 7529 | 7.4 | 15 | NR | NR | NR | NR |
Bustamente 26 | 763 | 6.4 | NR | NR | NR | NR | NR |
Kinnunen 27 | 72896§ | 3.2 | NR | NR | NR | NR | NR |
Dransfield 28 | 825 | 5.2 | NR | NR | NR | NR | NR |
Overall estimate based on all 16 studies % (95% CI)+ | 6.7 (5.7–7.7) | 18 (14–22) | 26 (20–32) | 33 (25–40) | 43 (37–50) | 51 (38–63) |
NR: not reported. #: follow-up <1.5 yrs; ¶: results year 1991; +: overall weighted average mortality rates based on random effects analysis; §: number of admissions instead of number of patients.